To supplement the already existing studies and reveal whether SGLT2 inhibitors exert beneficial effects in patients with heart failure regardless of ejection fraction, the EMPEROR-PRESERVED and DELIVER trials were conducted recently. Here, SLC5A2 is linked to heart failure.